MiNA reports preliminary Phase I data for liver cancer candidate

MiNA Therapeutics Ltd. (London, U.K.) reported preliminary data from 10 evaluable patients with advanced hepatocellular carcinoma (HCC)

Read the full 176 word article

User Sign In